Prodromos Sidiropoulos

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 23

Top Topics

Rheumatoid Arthritis

Disease Activity

Monoclonal Antibody

Top Venues

Annals of the rheumatic diseases

Rheumatology international

This page only lists publications with an associated author ORCID identifier.

Publications

Sofia Pitsigavdaki, Myrto Nikoloudaki, Panagiotis Garantziotis, Ettore Silvagni, Argyro Repa, Antonio Marangoni, Irini Flouri, Nestor Avgoustidis, Konstantinos Parperis, Antonis Fanouriakis, Marcello Govoni, Prodromos Sidiropoulos, Dimitrios T Boumpas, Alessandra Bortoluzzi, George K Bertsias
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression. Annals of the rheumatic diseases 83 (4) (2024)
Sofia Pitsigavdaki, Myrto Nikoloudaki, Panagiotis Garantziotis, Ettore Silvagni, Argyro Repa, Antonio Marangoni, Irini Flouri, Nestor Avgoustidis, Konstantinos Parperis, Antonis Fanouriakis, Marcello Govoni, Prodromos Sidiropoulos, Dimitrios T Boumpas, Alessandra Bortoluzzi, George K Bertsias
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression. Annals of the rheumatic diseases 83 (4) (2024)
Antonios Bertsias, Irini D Flouri, Argyro Repa, Nestor Avgoustidis, Eleni Kalogiannaki, Sofia Pitsigavdaki, George K Bertsias, Prodromos Sidiropoulos
Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with 'difficult to treat' rheumatoid arthritis. RMD open 10 (1) (2024)
Maria Pappa, Maria Kosmetatou, Antigone Pieta, Myrto Nikoloudaki, Nektarios Marios Liapis, Christina Tsalapaki, Aglaia Chalkia, Evangelia Argyriou, Theodoros Dimitroulas, Myrto Cheila, Georgios Demirtzoglou, Charalampos Papagoras, Andreas Goules, Christina Katsiari, Dimitrios Vassilopoulos, Prodromos Sidiropoulos, Kyriaki A Boki, Petros P Sfikakis, George Liapis, Harikleia Gakiopoulou, Paraskevi Vasileios Voulgari, Dimitrios T Boumpas, George K Bertsias, Maria G G Tektonidou, Antonis Fanouriakis
Attainment of EULAR/ERA-EDTA targets of therapy with current immunosuppressive regimens and adjustments in treatment: a multicentre, real-life observational study. RMD open 10 (3) (2024)
Sofia Pitsigavdaki, Myrto Nikoloudaki, Panagiotis Garantziotis, Ettore Silvagni, Argyro Repa, Antonio Marangoni, Irini Flouri, Nestor Avgoustidis, Konstantinos Parperis, Antonis Fanouriakis, Marcello Govoni, Prodromos Sidiropoulos, Dimitrios T Boumpas, Alessandra Bortoluzzi, George K Bertsias
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression. Annals of the rheumatic diseases 83 (4) (2024)
Antonios Bertsias, Irini D Flouri, Argyro Repa, Nestor Avgoustidis, Eleni Kalogiannaki, Sofia Pitsigavdaki, George K Bertsias, Prodromos Sidiropoulos
Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with 'difficult to treat' rheumatoid arthritis. RMD open 10 (1) (2024)
Sofia Pitsigavdaki, Myrto Nikoloudaki, Panagiotis Garantziotis, Ettore Silvagni, Argyro Repa, Antonio Marangoni, Irini Flouri, Nestor Avgoustidis, Konstantinos Parperis, Antonis Fanouriakis, Marcello Govoni, Prodromos Sidiropoulos, Dimitrios T Boumpas, Alessandra Bortoluzzi, George K Bertsias
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression. Annals of the rheumatic diseases (2024)
Antonios Bertsias, Irini D Flouri, Argyro Repa, Nestor Avgoustidis, Eleni Kalogiannaki, Sofia Pitsigavdaki, George K Bertsias, Prodromos Sidiropoulos
Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with 'difficult to treat' rheumatoid arthritis. RMD open 10 (1) (2024)
Sofia Pitsigavdaki, Myrto Nikoloudaki, Panagiotis Garantziotis, Ettore Silvagni, Argyro Repa, Antonio Marangoni, Irini Flouri, Nestor Avgoustidis, Konstantinos Parperis, Antonis Fanouriakis, Marcello Govoni, Prodromos Sidiropoulos, Dimitrios T Boumpas, Alessandra Bortoluzzi, George K Bertsias
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression. Annals of the rheumatic diseases 83 (4) (2024)
Antonios Bertsias, Irini D Flouri, Argyro Repa, Nestor Avgoustidis, Eleni Kalogiannaki, Sofia Pitsigavdaki, George K Bertsias, Prodromos Sidiropoulos
Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with 'difficult to treat' rheumatoid arthritis. RMD open 10 (1) (2024)
Sofia Pitsigavdaki, Myrto Nikoloudaki, Panagiotis Garantziotis, Ettore Silvagni, Argyro Repa, Antonio Marangoni, Irini Flouri, Nestor Avgoustidis, Konstantinos Parperis, Antonis Fanouriakis, Marcello Govoni, Prodromos Sidiropoulos, Dimitrios T Boumpas, Alessandra Bortoluzzi, George K Bertsias
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression. Annals of the rheumatic diseases 83 (4) (2024)
Panagiota Goutakoli, Garyfalia Papadaki, Argyro Repa, Nestor Avgoustidis, Eleni Kalogiannaki, Irini Flouri, Antonios Bertsias, Jerome Zoidakis, Martina K Samiotaki, George K Bertsias, Maria Semitekolou, Panayotis Verginis, Prodromos Sidiropoulos
A Peripheral Blood Signature of Increased Th1 and Myeloid Cells Combined with Serum Inflammatory Mediators Is Associated with Response to Abatacept in Rheumatoid Arthritis Patients. Cells 12 (24) (2023)
Irini D Flouri, Panagiota Goutakoli, Argyro Repa, Antonios Konstantinos Bertsias, Nestor Avgoustidis, Anastasios Eskitzis, Sofia Pitsigavdaki, Eleni Kalogiannaki, Maria Terizaki, George K Bertsias, Prodromos Sidiropoulos
Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study. Rheumatology international (2023)
Panagiota Goutakoli, Garyfalia Papadaki, Argyro Repa, Nestor Avgoustidis, Eleni Kalogiannaki, Irini Flouri, Antonios Bertsias, Jerome Zoidakis, Martina K Samiotaki, George K Bertsias, Maria Semitekolou, Panayotis Verginis, Prodromos Sidiropoulos
A Peripheral Blood Signature of Increased Th1 and Myeloid Cells Combined with Serum Inflammatory Mediators Is Associated with Response to Abatacept in Rheumatoid Arthritis Patients. Cells 12 (24) (2023)
Panagiota Goutakoli, Garyfalia Papadaki, Argyro Repa, Nestor Avgoustidis, Eleni Kalogiannaki, Irini Flouri, Antonios Bertsias, Jerome Zoidakis, Martina K Samiotaki, George K Bertsias, Maria Semitekolou, Panayotis Verginis, Prodromos Sidiropoulos
A Peripheral Blood Signature of Increased Th1 and Myeloid Cells Combined with Serum Inflammatory Mediators Is Associated with Response to Abatacept in Rheumatoid Arthritis Patients. Cells 12 (24) (2023)
Panagiota Goutakoli, Garyfalia Papadaki, Argyro Repa, Nestor Avgoustidis, Eleni Kalogiannaki, Irini Flouri, Antonios Bertsias, Jerome Zoidakis, Martina K Samiotaki, George K Bertsias, Maria Semitekolou, Panayotis Verginis, Prodromos Sidiropoulos
A Peripheral Blood Signature of Increased Th1 and Myeloid Cells Combined with Serum Inflammatory Mediators Is Associated with Response to Abatacept in Rheumatoid Arthritis Patients. Cells 12 (24) (2023)
Panagiota Goutakoli, Garyfalia Papadaki, Argyro Repa, Nestor Avgoustidis, Eleni Kalogiannaki, Irini Flouri, Antonios Bertsias, Jerome Zoidakis, Martina K Samiotaki, George K Bertsias, Maria Semitekolou, Panayotis Verginis, Prodromos Sidiropoulos
A Peripheral Blood Signature of Increased Th1 and Myeloid Cells Combined with Serum Inflammatory Mediators Is Associated with Response to Abatacept in Rheumatoid Arthritis Patients. Cells 12 (24) (2023)
Dimitrios Psaltis, Loukas Settas, Athanasios Georgiadis, Eftichia Koukli, Andreas Bounas, Achilleas Livieratos, Evangelia Petrikkou, Heleni Kalogiannaki, Argyro Repa, Dimitrios Vassilopoulos, Prodromos Sidiropoulos
The effects of golimumab on patient centric outcomes amongst rheumatoid arthritis patients in Greece. The GO-Q study. Rheumatology international 42 (4) (2022)
Antonios Bertsias, Nestor Avgoustidis, Ioannis Papalopoulos, Argyro Repa, Nikolaos Kougkas, Eleni Kalogiannaki, Georgios Bertsias, Irini Flouri, Prodromos Sidiropoulos
Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study. Arthritis research & therapy 24 (1) (2022)
Christina Adamichou, Irini Genitsaridi, Dionysis S Nikolopoulos, Myrto Nikoloudaki, Argyro Repa, Alessandra Bortoluzzi, Antonis Fanouriakis, Prodromos Sidiropoulos, Dimitrios T Boumpas, George K Bertsias
Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus. Annals of the rheumatic diseases (2021)
Irini Genitsaridi, Irini Flouri, Dimitris Plexousakis, Konstantinos Marias, Kyriaki Boki, Fotini Skopouli, Alexandros Drosos, George Bertsias, Dimitrios Boumpas, Prodromos Sidiropoulos
Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group. Arthritis research & therapy 22 (1) (2020)
Christina Adamichou, Dionysis Nikolopoulos, Irini Genitsaridi, Alessandra Bortoluzzi, Antonis Fanouriakis, Emmanouil Papastefanakis, Eleni Kalogiannaki, Irini Gergianaki, Prodromos Sidiropoulos, Dimitrios T Boumpas, George K Bertsias
In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment. Annals of the rheumatic diseases 79 (2) (2019)
Polina Putrik, Josef S Smolen, Francis Guillemin, Márta Péntek, Francisca Sivera, Tuulikki Sokka, Maarten de Wit, Anthony D Woolf, Angela Zink, Daina Andersone, Florian Berghea, Irena Butrimiene, Sandra Brouwer, Karen Cassar, Paraskevi Charalambous, Roberto Caporali, Elena Deseatnicova, Nemanja S Damjanov, Axel Finckh, Oliver FitzGerald, Gerður Gröndal, Nino Gobejishjvili, Piotr Gluszko, Marco Hirsch, Igor Jovanovic, Jiří Vencovský, Xavier Janssens, Andras P Keszei, Maria Kovarova, Mart Kull, Luís Cunha Miranda, Miroslav Mayer, Snezana Misevska-Percinkova, Nevsun Inanc, Oleg Nadashkevich, Ingemar F Petersson, Kari Puolakka, Bernadette Rojkovich, Helga Radner, Fruzsina Szabados, Gleb Slobodin, Ivan Shirinsky, Nikolay Soroka, Prodromos Sidiropoulos, Russka Shumnalieva, Sekib Sokolovic, Surayo Shukurova, Argjend Tafaj, Matija Tomšič, Till Uhlig, Suzanne M M Verstappen, Annelies Boonen
Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries. Annals of the rheumatic diseases 78 (11) (2019)